Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials

Bibliography

• Whiting DR, Guariguata L, Weil C, IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21
   PubMed Web of Science ®Google Scholar
• Muller-Nordhorn J, Binting S, Roll S, An update on regional variation in cardiovascular mortality within Europe. Eur. Heart J 2008;29:1316-26
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care 2012;35:S11-63
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Senecal M, Fodor G, Gagne C, Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study–observational. Curr Med Res Opin 2009;25:47-55
   PubMed Web of Science ®Google Scholar
• Suksomboon N, Poolsup N, Boonkaew S, Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol 2011;137:1328-33
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Ertek S. Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. Nutr Diet Suppl 2009;1:1-10
   Google Scholar
• Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 1997;2:94-103
   Google Scholar
• Kong WJ, Zhang H, Song DQ, Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009;58:109-19
   PubMed Web of Science ®Google Scholar
• Ko BS, Choi SB, Park SK, Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull 2005;28:1431-7
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu YC, Guo FJ, Antidiabetic effects of cinnamaldehyde and berberine and their impacts on retinol binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J 2008;121:2124-8
   PubMed Web of Science ®Google Scholar
• Yin J, Hu R, Chen M, Effects of berberine on glucose metabolism in vitro. Metabolism 2002;51:1439-43
   PubMed Web of Science ®Google Scholar
• Lu SS, Yu YL, Zhu HJ, Berberine promotes glucagons like peptide-1(7-36 amide) secretion in streptozocin-induced diabetic rats. J Endocrinol 2009;200:159-65
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Lu FE, Leng SH, Facilitating effects of berberine on rat pancreatic islets Through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity. World J Gastroenterol 2008;14:6004-11
   PubMed Web of Science ®Google Scholar
• Leng S, Lu F, Xu L. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004;25:496-502
   PubMed Web of Science ®Google Scholar
• Xia X, Weng J. Targeting metabolic syndrome: candidate natural agents. J Diabetes 2010;2:243-9
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang X, Shao L, Berberine acutely inhibits insulin secretion from beta-cells through 3′,5′-cyclic adenosine 5′-monophosphate signaling pathway. Endocrinology 2008;149:4510-18
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou S, Tang J, Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol 2009;606:262-8
   PubMed Web of Science ®Google Scholar
• Turner N, Li JY, Gosby A, Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008;57:1414-18
   PubMed Web of Science ®Google Scholar
• Xia X, Yan J, Shen Y, Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS one 2011;6:e16556
   PubMed Web of Science ®Google Scholar
• Ma X, Egawa T, Kimura H, Berberine-induced activation of 5′-adenosine monophosphate-activated protein kinase and glucose transport in rat skeletal muscles. Metabolism 2010;59:1619-27
   PubMed Web of Science ®Google Scholar
• Xie X, Li W, Lan T, Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway. Endocr J 2011;58:761-8
   PubMed Web of Science ®Google Scholar
• Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008;22:999-1012
   PubMed Web of Science ®Google Scholar
• Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111
   PubMedGoogle Scholar
• Yi P, Lu FE, Xu LJ, Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World J Gastroenterol 2008;14:876-83
   PubMed Web of Science ®Google Scholar
• Xing LJ, Zhang L, Liu T, Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol 2011;668:467-1
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin EJ, Kim ED, Berberine activated GLUT-1-mediated glucose uptake in 3T3-L1 adipocytes. Biol Pharm Bull 2007;30:2120-5
   PubMed Web of Science ®Google Scholar
• Yin J, Gao Z, Liu D, Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008;294:E148-56
   PubMed Web of Science ®Google Scholar
• Zhou L, Yang Y, Wang X, Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007;56:405-12
   PubMed Web of Science ®Google Scholar
• Cheng Z, Pang T, Gu M, Berberine stimulated glucose uptake in L6 myotubes includes both AMPK and p 38 MAPK. Biochim Biophys Acta 2006;1760:1682-9
   PubMed Web of Science ®Google Scholar
• Zhou JY, Zhou SW, Zhang KB, Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 2008;31:1169-76
   PubMed Web of Science ®Google Scholar
• Huang C, Zhang Y, Gong Z, Berberine inhibits 3T3L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun 2006;348:571-8
   PubMed Web of Science ®Google Scholar
• Wang SH, Wang WJ, Wang XF, Effects of Astragalus polysaccharides and berberine on carbohydrate metabolism and cell differentiation in 3T3-L1 adipocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24:926-8
   PubMedGoogle Scholar
• Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit 2011;17:RA164-7
   PubMed Web of Science ®Google Scholar
• Xie W, Gu D, Li J, Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS one 2011;6:e24520
   PubMed Web of Science ®Google Scholar
• Liu WH, Hei ZQ, Nie H, Berberine ameliorates renal injury in streptozocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 2008;121:706-12
   PubMed Web of Science ®Google Scholar
• Liu W, Tang F, Deng Y, Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition. Mol Cell Biochem 2009;325:99-105
   PubMed Web of Science ®Google Scholar
• Abidi P, Zhou Y, Jiang JD, Extracellular signal regulated kinase–dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005;25:2170-6
   PubMed Web of Science ®Google Scholar
• Lee S, Lim HJ, Park JH, Berberine induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 2007;362:853-7
   PubMed Web of Science ®Google Scholar
• Cameron J, Ranheim T, Kulseth MA, Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008;201:266-73
   PubMed Web of Science ®Google Scholar
• Li H, Park S, Lee H-S, Liu J. HNF1alpha plays a critical role in pcsk9 gene transcription and regulation by a natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95
   PubMed Web of Science ®Google Scholar
• Li H, Chen W, Zhou Y, Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements. J Lipid Res 2009;50:820-31
   PubMed Web of Science ®Google Scholar
• Choi BH, Ahn IS, Kim YH, Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 2006;38:599-605
   PubMed Web of Science ®Google Scholar
• Brusq JM, Ancellin N, Grondin P, Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006;47:1281-8
   PubMed Web of Science ®Google Scholar
• Fatehi-Hassanabad Z, Jafarzadeh M, Tarhini A, The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats. Phytother Res 2005;19:222-5
   PubMed Web of Science ®Google Scholar
• Peychev L.. Pharmacological investigation on the cardiovascular effects of berberine vulgaris on tested animals. Pharmacia 2005;52:118-21
   Google Scholar
• Chun YT, Yip TT, Lau KL, A biochemical study on hypotensive effects of berberine in rats. Gen Pharmacol 1979;10:177-82
   PubMedGoogle Scholar
• Wong KK. Mechanism of the aortic relaxation induced by low concentrations of berberine. Planta Med 1998;64:756-7
   PubMed Web of Science ®Google Scholar
• Ko WH, Yao XQ, Lau CW, Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol 2000;399:187-96
   PubMed Web of Science ®Google Scholar
• Kang DG, Sohn EJ, Kwon EK, Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vascul Pharmacol 2002;39:281-6
   PubMed Web of Science ®Google Scholar
• Olmez E, Ilhan M. Evaluation of the alpha-adrenoceptor antagonistic action of berberine in isolated organs. Arzneimittelforschung 1992;42:1095-7
   PubMed Web of Science ®Google Scholar
• Chiou WE, Yen MH, Chen CF. Mechanism of vasodilatory effect of berberine in rat mesenteric artery. Eur J Pharmacol 1991;204:35-40
   PubMed Web of Science ®Google Scholar
• Pan LR, Tang Q, Fu Q, Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol Sin 2005;26:1334-8
   PubMed Web of Science ®Google Scholar
• Ko WH, Yao XO, Lau CW, Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol 2000;399:187-96
   PubMed Web of Science ®Google Scholar
• Liang KW, Yin SC, Ting CT, Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK–dependent pathway in vascular smooth muscle cells. Eur J Pharmacol 2008;590:343-54
   PubMed Web of Science ®Google Scholar
• Liang KW, Ting CT, Yin SC, Berberine suppresses MEK/ERK-dependent Egr-1 signalling pathway and inhibits vascular smooth muscle regrowth after in vitro mechanical injury. Biochem Pharmacol 2006;71:806-17
   PubMed Web of Science ®Google Scholar
• Cho BJ, Im EK, Kwon JH, Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1,2 pathway in smooth muscle cells. Mol Cells 2005;20:429-34
   PubMed Web of Science ®Google Scholar
• Hong Y, Hui SS, Chan BT, Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci 2003;72:2499-507
   PubMed Web of Science ®Google Scholar
• Hong Y, Hui SC, Chan TY, Effect of berberine on regression of pressure overload induced cardiac hypertrophy in rats. Am J Chin Med 2002;30:589-99
   PubMed Web of Science ®Google Scholar
• Huang WM, Yan H, Jin JM, Beneficial effects of berberine on hemodynamics during acute ischemic left ventricular failure in dogs. Chin Med J 1992;105:1014-19
   PubMed Web of Science ®Google Scholar
• Wang YX, Zheng YM, Zhou XB. Inhibitory effects of berberine on ATP-sensitive K+ channels in cardiac myocytes. Eur J Pharmacol 1996;316:307-15
   PubMed Web of Science ®Google Scholar
• Tan W, Lu J, Huang M, Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 2011;6:27
   PubMed Web of Science ®Google Scholar
• Guo Y, Pope C, Cheng X, Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol 2011;138:111-18
   PubMed Web of Science ®Google Scholar
• Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab Dispos 2004;32:405-12
   PubMed Web of Science ®Google Scholar
• Lan T, Shen X, Liu P, Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway. Arch Biochem Biophys 2010;502(2):112-20
   PubMed Web of Science ®Google Scholar
• Liu L, Yu YL, Yang JS, Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 2010;381:371-81
   PubMed Web of Science ®Google Scholar
• Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-17
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei J, Xue R, Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010;59:285-92
   PubMed Web of Science ®Google Scholar
• Gu Y, Zhang Y, Shi X, Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010;81:766-72
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li X, Zou D, Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93(7):2559-65
   PubMed Web of Science ®Google Scholar
• Affuso F, Ruvolo A, Micillo F, Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010;20:656-61
   PubMed Web of Science ®Google Scholar
• Affuso F, Mercurio V, Ruvolo A, A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;4:77-83
   PubMedGoogle Scholar
• Cheng F, Wang Y, Li J, Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int J Cardiol 2012; doi: https://doi.org/10.1016/j.ijcard.2012.03.090
   Google Scholar
• Cicero A, Derosa G, Maffioli P, Long-term effects of a berberine based nutraceutical on body weight and insulin-sensitivity in nondiabetic hyperlipidaemic patients. J Hypert 2011;29(e-Suppl A):e160
   Google Scholar
• Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007;57:26-30
   PubMed Web of Science ®Google Scholar
• Kong WJ, Wei J, Zuo ZY, Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008;57:1029-37
   PubMed Web of Science ®Google Scholar
• Xu MG, Wang JM, Chen L, Berberine-induced upregulation of endothelial progenitor cells in related to nitric oxide production in healthy subjects. Cardiology 2008;112:279-86
   PubMed Web of Science ®Google Scholar
• Xu MG, Wang JM, Chen L, Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity. J Hum Hypertens 2008;22:389-93
   PubMed Web of Science ®Google Scholar
• Wang JM, Yang Z, Xu MG, Berberine induced decline in circulating CD31(+)/CD42(-) microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol 2009;614:77-83
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Maciel BC, Secches AL, Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol 1988;11:253-60
   PubMed Web of Science ®Google Scholar
• Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92:173-6
   PubMed Web of Science ®Google Scholar
• Lau CW, Yao XQ, Chen ZY, Cardiovascular actions of berberine. Cardiovasc Drug Rev 2001;19:234-44
   PubMed Web of Science ®Google Scholar
• Huang CG, Chu ZL, Wei SJ, Effects of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells. Thromb Res 2002;106(4–5):223-7
   PubMed Web of Science ®Google Scholar
• Huang CG, Chu ZL, Yang ZM. The progress in pharmacological researches on berberine. Comun Inform Pharm 1991;9:10-12
   Google Scholar
• Hoy EW, Akhmedov A, Luscher TF, Berberine a natural lipid-lowering drug, exerts prothrombic effects on vascular cells. J Mol Cell Cardiol 2009;46:234-40
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang QZ, Li FM, Biochemical pathways in the antiatherosclerotic effect of berberine. Chin Med J (Eng) 2008;121:1197-203
   PubMed Web of Science ®Google Scholar
• Pandey MK, Sung B, Kunnumakkara AB, Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappa-B-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008;68:5370-9
   PubMed Web of Science ®Google Scholar
• Hwang JM, Wang CJ, Chou FP, Inhibitory effect of berberine on tert-butyl- hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 2002;76:664-70
   PubMed Web of Science ®Google Scholar
• Kong W, Wei J, Abidi P, Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10(12):1344-51
   PubMed Web of Science ®Google Scholar
• Zhao W, Xue R, Zhou ZX, Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother 2008;62(10):730-1
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Ertek S. Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? Med J Nutr Metab 2008;1(2):85-93
   Google Scholar